Welcome to our dedicated page for ClearPoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported routine insider activity involving company common stock. He acquired 1,361 shares of common stock on June 30, 2026 as a grant/award under the company’s Employee Stock Purchase Plan (ESPP) at $11.93 per share. The ESPP purchase covered the period from January 1, 2026 through June 30, 2026, with shares bought at 85% of the lower of the fair market value on the first or last day of that period. Following this ESPP acquisition, Burnett directly owns 118,203 shares of ClearPoint Neuro common stock and indirectly has 191,388 shares held through the Joseph M. Burnett Trust dated October 20, 2022, where he serves as trustee.
ClearPoint Neuro, Inc. director and CEO Joseph Burnett reported an option exercise and related share sale in Common Stock. He exercised stock options to acquire 20,000 shares at $2.50 per share and sold 20,000 shares in an open-market transaction at a weighted average price of $19.38 per share.
Following these transactions, he holds 116,842 shares directly and 191,388 shares indirectly through the Joseph M. Burnett Trust. The filing notes the exercise and sale were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.
CLPT notice of proposed sale: a planned sale of 20,000 shares of Common Stock via exercise of stock options for cash on 06/29/2026. The filing also records prior 10b5-1 transactions on 06/17/2026 totaling 61,843 shares (60,000 and 1,843) with disclosed proceeds of $1,067,204.00 and $33,060.84, respectively.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported an exercise-and-sell transaction in company stock. He exercised stock options for 60,000 shares of common stock at $2.50 per share and sold 60,000 shares held directly at a weighted average price of $17.79 per share. In a separate indirect transaction, the Joseph M. Burnett Trust dated 10/20/2022, for which he serves as trustee, sold 1,843 shares at a weighted average price of $17.94 per share. Following these transactions, Burnett held 116,842 shares directly and 191,388 shares indirectly through the trust, and the option award referenced in the filing covered 270,000 shares after the exercise. The filing notes that the option exercise and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.
ClearPoint Neuro, Inc. director Timothy T. Richards exercised stock options and had shares withheld to cover taxes. He exercised options for 500 shares of Common Stock at $10.00 per share and 376 shares were disposed of at $13.30 per share for tax-withholding. Following these transactions, he directly owned 87,322 Common Stock shares, and the exercised option grant was fully used.
ClearPoint Neuro director Timothy T. Richards sold 5,415 shares of Common Stock. The open-market sale on June 1, 2026 was executed at a weighted average price of $12.17 per share, with individual trades ranging from $12.04 to $12.47 per share.
According to the filing, the sale was made to cover the tax liability associated with the vesting of 12,417 restricted stock units on May 19, 2026. After this transaction, Richards directly holds 87,198 shares of ClearPoint Neuro common stock.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the proposed sale of 5,145 shares of Common Stock. The filing lists an aggregate value of $62,611.56 and reports 29,989,563 shares outstanding as of 06/01/2026 as context. The shares arose from restricted stock vesting under a registered plan on 05/20/2026.